Fountain Partners Blog Cytovance Biologics Acquired

According  to PEHub  : “Cytovance® Biologics, Inc. (“Cytovance”), a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing company (CDMO),  announced today that it has been acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. Through the Cytovance acquisition, Hepalink USA Inc. and its parent company Shenzhen Hepalink Pharmaceutical Co., […]